ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "registry and remission"

  • Abstract Number: 2518 • 2014 ACR/ARHP Annual Meeting

    What Is the Level of Agreement Between Disease Activity Indices and Response Criteria Among Rheumatoid Arthritis Patients Treated with TNF Inhibitors?

    Edward C. Keystone1, Philip Baer2, J. Antonio Avina-Zubieta3, Anna Jaroszynska4, Jude Rodrigues5, Regan Arendse6, Dalton Sholter7, Michael Starr8, Ariel Masetto9, John S. Sampalis10, Emmanouil Rampakakis10, Francois Nantel11, May Shawi11, Allen J Lehman12 and Susan Otawa12, 1Medicine, University of Toronto, Toronto, ON, Canada, 2Private Practice, Scarborough, ON, Canada, 3Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, 4Private Practice, Burlington, ON, Canada, 5Clinical Research and Arthritis Centre, Windsor, ON, Canada, 6University of Saskatchewan, Saskatoon, SK, Canada, 7University of Alberta, Edmonton, AB, Canada, 8Rheumatology, McGill University Health Centre, Montreal, QC, Canada, 9Rheumatology, CHUS, Fleurimont, QC, Canada, 10JSS Medical Research, Montreal, QC, Canada, 11Janssen Inc., Toronto, ON, Canada, 12Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose: Several standardized response criteria and disease activity indices are used to assess treatment efficacy in rheumatoid arthritis (RA). These measures comprise different types and…
  • Abstract Number: 956 • 2014 ACR/ARHP Annual Meeting

    Real-World Validation of the Minimal Disease Activity Index in Psoriatic Arthritis: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada

    Proton Rahman1, Saeed Shaikh2, Michael Starr3, William Bensen4, Denis Choquette5, Wojciech Olszynski6, Maqbool Sheriff7, Michel Zummer8, Emmanouil Rampakakis9, John S. Sampalis9, Allen J Lehman10, Susan Otawa10, Francois Nantel11, Vincent Letourneau11 and May Shawi11, 1Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 2McMaster University, Hamilton, ON, Canada, 3Montreal General Hospital, Montreal, QC, Canada, 4Division of Rheumatology, McMaster University, Hamilton, ON, Canada, 5Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, 6University of Saskatchewan, Saskatoon, SK, Canada, 7Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 8Université de Montréal, Montreal, QC, Canada, 9JSS Medical Research, Montreal, QC, Canada, 10Medical Affairs, Janssen Inc., Toronto, ON, Canada, 11Janssen Inc., Toronto, ON, Canada

    Background/Purpose A definition of minimal disease activity (MDA) in PsA was derived from the opinion of 60 PsA experts including fulfillment of ≥5 of the…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.